18 reports of this reaction
1.6% of all TRIFLURIDINE reports
#17 most reported adverse reaction
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME is the #17 most commonly reported adverse reaction for TRIFLURIDINE, manufactured by Sandoz Inc. There are 18 FDA adverse event reports linking TRIFLURIDINE to PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME. This represents approximately 1.6% of all 1,094 adverse event reports for this drug.
Patients taking TRIFLURIDINE who experience palmar plantar erythrodysaesthesia syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME is a less commonly reported adverse event for TRIFLURIDINE, but still significant enough to appear in the safety profile.
In addition to palmar plantar erythrodysaesthesia syndrome, the following adverse reactions have been reported for TRIFLURIDINE:
The following drugs have also been linked to palmar plantar erythrodysaesthesia syndrome in FDA adverse event reports:
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME has been reported as an adverse event in 18 FDA reports for TRIFLURIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME accounts for approximately 1.6% of all adverse event reports for TRIFLURIDINE, making it a notable side effect.
If you experience palmar plantar erythrodysaesthesia syndrome while taking TRIFLURIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.